JUN 19, 2018 10:34 PM PDT

Triple Negative Breast Cancer: Treatment Using Innovative Drug Technology

WRITTEN BY: Nouran Amin
2 2 118

Researchers at Purdue University have created innovative drug technology that may seek to treat one of the most aggressive forms of breast cancer: triple negative breast cancer.

In the United States, triple negative breast cancer (TNBC) occurs in about 10-20% of diagnosed breast cancers. It is also more likely to affect younger people, African Americans, Hispanics, and/or those with a BRCA1 gene mutation.

Currently, the only treatment option for TNBC is chemotherapy. However, chemotherapy is not effective to the degree that it targets cancer cells. Additionally, chemotherapy causes unpleasant side-effects that are often debilitating. Therefore, the need for an innovative targeted therapy that will treat TNBC without adverse effects is stronger than ever.

“TNBC is a very aggressive type of breast cancer with a short survival rate due to lack of available therapeutic drugs used for treatment that will cause minimal side effects,” explains research team leader Meden Isaac-Lam and an associate professor in the Department of Chemistry and Physics at Purdue University Northwest. “There are no known recognized molecular targets for TNBC, making the design of highly specific drugs extremely challenging.”

The Isaac-Lam research team produced drug candidates that are strong at lower concentrations than traditional chemotherapy. This technology utilizes molecules that can be selectively activated by light and absorbed by cancer cells. The therapy is believed to decrease the dosage needed to administer the drug, ultimately reducing side effects and effective in treating TNBC.

“Our proposed solution is to design drugs that target vitamin receptors produced excessively in cancer cells, which compete with normal cells for the vitamins necessary for cellular growth and proliferation,” Isaac-Lam said. “Attaching vitamins on compounds that are light-activated and that are known to be taken up by tumor cells will provide a means of selectively accumulating these synthetic drug-vitamin conjugates in cancer cells more than in healthy cells.”

The technology works by injecting the selected compound into the patient where it accumulates into the cancer cells. These cancer cells are then killed when activated by light.

“This will be an alternative solution to the available therapies that are not selective to the tumor cells causing detrimental effects to the patient’s healthy cells,” Isaac-Lam said. “The technology can be an effective treatment for breast cancer patients who are not responding to the standard conventional therapy.”

Fortunately, these drug candidates that were screened for TNBT may be effective in treatments for other forms of breast cancer.

Sources: Purdue University

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAR 10, 2018
Drug Discovery
MAR 10, 2018
Treatment Intended for Osteoarthritis, Decreases Opioid Dependence
Treatment intended for osteoarthritis succeeds in decreasing symptoms of an opioid addiction.
MAR 20, 2018
Drug Discovery
MAR 20, 2018
The 'Molecular Key' in Developing Tuberculosis Drugs
Tuberculosis is an ancient disease, signs of it were examined in Egyptian mummies. It is caused by the bacterium and pathogen, Mycobacterium tuberculosis,
MAR 24, 2018
Drug Discovery
MAR 24, 2018
A Modified Version of Herpes Simplex Virus-1 May Cure Advanced-Stage Liver Tumors
A recent study showcased in the Society of Interventional Radiology Annual Scientific Meeting explains that liver Tumors, in an advanced stage, can be safe
APR 09, 2018
Drug Discovery
APR 09, 2018
Molecularly Attacking Transthyretin Amyloidosis (ATTR)
Transthyretin amyloidosis (ATTR) is a slowly progressive disease characterized by the buildup of abnormal deposits of a protein known as amyloid present in
MAY 02, 2018
Drug Discovery
MAY 02, 2018
New Kind of Sedative for Violent Patients
A new drug developed in Australia by Queensland Ambulance Service (QAS) can effectively calm down violent patients. The drug is droperidol and was found to
JUN 13, 2018
Drug Discovery
JUN 13, 2018
Small Molecule Seeks To Treat Asthma Attacks
For many individuals with asthma, a tiny particle almost invisible can trigger an asthmatic attack if it enters the airways of the respiratory system. Asth
Loading Comments...